Demystifying heparan sulfate-protein interactions

Annual Review of Biochemistry

Volumn 83, Issue , 2014, Pages 129-157

  Xu, Ding ^a   Esko, Jeffrey D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

glycan protein interaction; glycosaminoglycan; heparan sulfate binding domain; heparin binding protein; oligomerization; proteoglycan

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID PRECURSOR PROTEIN; ANTITHROMBIN; ARGININE; CHEMOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARAN SULFATE; HEPARIN BINDING PROTEIN; LYSINE; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEOHEPARAN SULFATE; THROMBIN; BETA GLUCURONIDASE; CARBOHYDRATE; HEPARANASE; LIGAND; MACROMOLECULE; OLIGOSACCHARIDE; PROTEIN; PROTEIN BINDING; PROTEOGLYCAN;

BINDING SITE; HYDROGEN BOND; MOLECULAR EVOLUTION; MOLECULAR SIZE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; ANIMAL; CHEMISTRY; EXTRACELLULAR MATRIX; HUMAN; MACROMOLECULE; METABOLISM; PROTEIN ANALYSIS; PROTEIN SECONDARY STRUCTURE;

ANIMALS; BINDING SITES; CARBOHYDRATES; EXTRACELLULAR MATRIX; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; HYDROGEN BONDING; LIGANDS; MACROMOLECULAR SUBSTANCES; OLIGOSACCHARIDES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, SECONDARY; PROTEINS; PROTEOGLYCANS;

EID: 84902215812     PISSN: 00664154     EISSN: 15454509     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-060713-035314     Document Type: Review

References (148)

1. GuerardelY,Czeszak X, Sumanovski LT,Karamanos Y, PopescuO, et al. 2004. Molecular fingerprinting of carbohydrate structure phenotypes of three Porifera proteoglycan-like glyconectins. J. Biol. Chem. 279:15591-603
2. Yamada S, Morimoto H, Fujisawa T, Sugahara K. 2007. Glycosaminoglycans in Hydra magnipapillata (Hydrozoa, Cnidaria): demonstration of chondroitin in the developing nematocyst, sting organelle, and structural characterization of glycosaminoglycans. Glycobiology 17:886-94
3. Lawrence R, Olson SK, Steele RE, Wang L, Warrior R, et al. 2008. Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J. Biol. Chem. 283:33674-84
4. Ori A, Wilkinson MC, Fernig DG. 2011. A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J. Biol. Chem. 286:19892-904
5. Bishop JR, Schuksz M, Esko JD. 2007. Heparan sulphate proteoglycans fine-Tunemammalian physiology. Nature 446:1030-37
6. Lin X, Wei G, Shi ZZ, Dryer L, Esko JD, et al. 2000. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev. Biol. 224:299-311
7. Stickens D, Zak BM, Rougier N, Esko JD, Werb Z. 2005. Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development 132:5055-68
8. Maccarana M, Sakura Y, Tawada A, Yoshida K, Lindahl U. 1996. J. Biol. Chem. 271:17804-10
9. Murphy KJ, Merry CL, Lyon M, Thompson JE, Roberts IS, Gallagher JT. 2004. J. Biol. Chem. 279:27239-45
10. Esko JD, Selleck SB. 2002. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71:435-71
11. LawrenceR,Brown JR,Al-MafrajiK,LamannaWC,Beitel JR, et al. 2012. Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat. Chem. Biol. 8:197-204
12. Carlsson P, Kjelleacute;n L. 2012. Heparin biosynthesis. Handb. Exp. Pharmacol. 207:23-41
13. Kreuger J, Kjelleacute;n L. 2012. Heparan sulfate biosynthesis: regulation and variability. J. Histochem. Cytochem. 60:898-907
14. Esko JD, Sharon N. 2009. Microbial lectins: hemagglutinins, adhesins, and toxins. In Essentials of Glycobiology, ed. A Varki, RD Cummings, JD Esko, HH Freeze, P Stanley, et al., pp. 489-500. Cold Spring Harbor, N.Y.: Cold Spring Harb. Lab.
15. Esko JD, Linhardt RJ. 2009. Proteins that bind sulfated glyocosaminoglycans. In Essentials of Glycobiology, ed. A Varki, RD Cummings, JD Esko, HH Freeze, P Stanley, et al., pp. 501-12. Cold Spring Harbor, N.Y.: Cold Spring Harb. Lab.
16. IshiharaM, Fedarko NS, Conrad HE. 1986. Transport of heparan sulfate into the nuclei of hepatocytes. J. Biol. Chem. 261:13575-80
17. Richardson TP, Trinkaus-Randall V, Nugent MA. 2001. Regulation of heparan sulfate proteoglycan nuclear localization by fibronectin. J. Cell Sci. 114:1613-23
18. Chen L, Sanderson RD. 2009. Heparanase regulates levels of syndecan-1 in the nucleus. PLoS ONE 4:e4947
19. Zong F, Fthenou E, Wolmer N, Holl ösi P,Kovalszky I, et al. 2009. Syndecan-1 and FGF-2, but not FGF receptor-1, share a commontransport route and co-localize with heparanase in the nuclei ofmesenchymal tumor cells. PLoS ONE 4:e7346
20. Varki A, Etzler ME, Cummings RD, Esko JD. 2009. Discovery and classification of glycan-binding proteins. In Essentials of Glycobiology, ed. A Varki, RD Cummings, JD Esko, HH Freeze, P Stanley, et al., pp. 375-86. Cold Spring Harbor, N.Y.: Cold Spring Harb. Lab.
21. Radek KA, Taylor KR,Gallo RL. 2009. FGF-10 and specific structural elements of dermatan sulfate size and sulfation promote maximal keratinocyte migration and cellular proliferation. Wound Repair Regen. 17:118-26
22. Taylor KR,Rudisill JA, Gallo RL. 2005. Structural and sequencemotifs in dermatan sulfate for promoting fibroblast growth factor 2 (FGF-2) and FGF-7 activity. J. Biol. Chem. 280:5300-6
23. Trowbridge JM, Rudisill JA, Ron D, Gallo RL. 2002. Dermatan sulfate binds and potentiates activity of keratinocyte growth factor (FGF-7). J. Biol. Chem. 277:42815-20
24. Trowbridge JM, Gallo RL. 2002. Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 12:R117-25
25. Ori A, Wilkinson MC, Fernig DG. 2008. The heparanome and regulation of cell function: structures, functions and challenges. Front. Biosci. 13:4309-38
26. Faller B, Mely Y, Gerard D, Bieth JG. 1992. Heparin-induced conformational change and activation of mucus proteinase inhibitor. Biochemistry 31:8285-90
27. Olson ST, Halvorson HR, Björk I. 1991. Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. J. Biol. Chem. 266:6342-52
28. Friedrich U, Blom AM, Dahlbck B, Villoutreix BO. 2001. Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. J. Biol. Chem. 276:24122-28
29. Thompson LD, Pantoliano MW, Springer BA. 1994. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 33:3831-40
30. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, et al. 2009. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J. Clin. Investig. 119:3236-45
31. Mascotti DP, Lohman TM. 1995. Thermodynamics of charged oligopeptide-heparin interactions. Biochemistry 34:2908-15
32. Sheinerman FB, Norel R, Honig B. 2000. Electrostatic aspects of protein-protein interactions. Curr. Opin. Struct. Biol. 10:153-59
33. Duchesne L, Octeau V, Bearon RN, Beckett A, Prior IA, et al. 2012. Transport of fibroblast growth factor 2 in the pericellular matrix is controlled by the spatial distribution of its binding sites in heparan sulfate. PLoS Biol. 10:e1001361
34. Sadir R, Imberty A, Baleux F, Lortat-Jacob H. 2004. Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor 1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J. Biol. Chem. 279:43854-60
35. Lortat-Jacob H, Baltzer F, Grimaud JA. 1996. Heparin decreases the blood clearance of interferon-γ and increases its activity by limiting the processing of its carboxyl-Terminal sequence. J. Biol. Chem. 271:16139-43
36. Yan D, Lin X. 2009. Shaping morphogen gradients by proteoglycans. Cold Spring Harb. Perspect. Biol. 1:a002493
37. Bellaiche Y, The I, Perrimon N. 1998. Tout-velu is a Drosophila homologue of the putative tumour suppressor EXT-1 and is needed for Hh diffusion. Nature 394:85-88
38. Baeg GH, Lin X, KhareN, Baumgartner S, PerrimonN. 2001. Heparan sulfate proteoglycans are critical for the organization of the extracellular distribution ofWingless. Development 128:87-94
39. Takei Y,Ozawa Y, SatoM,Watanabe A,TabataT. 2004. Three Drosophila EXT genes shape morphogen gradients through synthesis of heparan sulfate proteoglycans. Development 131:73-82
40. Han C, Yan D, Belenkaya TY, Lin X. 2005. Drosophila glypicans Dally and Dally-like shape the extracellular Wingless morphogen gradient in the wing disc. Development 132:667-79
41. Lei J,Wan FY, Lander AD, Nie Q. 2011. Robustness of signaling gradient in Drosophila wing imaginal disc. Discret. Contin. Dyn. Syst. B 16:835-66
42. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, et al. 1999. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5:495-502
43. BulowHE, Hobert O. 2006. Themolecular diversity of glycosaminoglycans shapes animal development. Annu. Rev. Cell Dev. Biol. 22:375-407
44. Lortat-Jacob H. 2009. The molecular basis and functional implications of chemokine interactions with heparan sulphate. Curr. Opin. Struct. Biol. 19:543-48
45. Weber M, Sixt M. 2013. Live cell imaging of chemotactic dendritic cell migration in explanted mouse ear preparations. Methods Mol. Biol. 1013:215-26
46. Goodsell DS, Olson AJ. 2000. Structural symmetry and protein function. Annu. Rev. Biophys. Biomol. Struct. 29:105-53
47. Belov AA, Mohammadi M. 2013. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb. Perspect. Biol. 5:a015958
48. Mohammadi M, Olsen SK, Ibrahimi OA. 2005. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16:107-37
49. DiGabriele AD, Lax I,Chen DI, SvahnCM, Jaye M, et al. 1998. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 393:812-17
50. Brown A, Robinson CJ, Gallagher JT, Blundell TL. 2013. Cooperative heparin-mediated oligomerization of fibroblast growth factor 1 (FGF1) precedes recruitment of FGFR2 to ternary complexes. Biophys. J. 104:1720-30
51. Pellegrini L, Burke DF,Von Delft F,Mulloy B, BlundellTL. 2000. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407:1029-34
52. Beenken A, Eliseenkova AV, Ibrahimi OA, Olsen SK, Mohammadi M. 2012. Plasticity in interactions of fibroblast growth factor 1 (FGF1) N terminus with FGF receptors underlies promiscuity of FGF1. J. Biol. Chem. 287:3067-78
53. Xu D, Young JH, Krahn JM, Song D, Corbett KD, et al. 2013. Stable RAGE-heparan sulfate complexes are essential for signal transduction. Am. Chem. Soc. Chem. Biol. 8:1611-20
54. Xu D, Young J, Song D, Esko JD. 2011. Heparan sulfate is essential for high mobility group protein 1 (HMGB1) signaling by the receptor for advanced glycation end products (RAGE). J. Biol. Chem. 286:41736-44
55. Thinakaran G, Koo EH. 2008. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283:29615-19
56. Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, et al. 2004. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 23:4106-15
57. Soba P, Eggert S, Wagner K, Zentgraf H, Siehl K, et al. 2005. Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J. 24:3624-34
58. Dyrks T, Weidemann A, Multhaup G, Salbaum JM, Lemaire HG, et al. 1988. Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimers disease. EMBO J. 7:949-57
59. Xue Y, Lee S, Wang Y, Ha Y. 2011. Crystal structure of the E2 domain of amyloid precursor protein-like protein 1 in complex with sucrose octasulfate. J. Biol. Chem. 286:29748-57
60. Gralle M, BotelhoMG, Wouters FS. 2009. Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. J. Biol. Chem. 284:15016-25
61. Mok SS, Sberna G, Heffernan D, Cappai R, Galatis D, et al. 1997. Expression and analysis of heparinbinding regions of the amyloid precursor protein of Alzheimers disease. FEBS Lett. 415:303-7
62. Lee S, Xue Y, Hu J, Wang Y, Liu X, et al. 2011. The E2 domains of APP and APLP1 share a conserved mode of dimerization. Biochemistry 50:5453-64
63. Rossjohn J, Cappai R, Feil SC, Henry A,McKinstry WJ, et al. 1999. Crystal structure of theN-Terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat. Struct. Biol. 6:327-31
64. Dahms SO, Hoefgen S, Roeser D, Schlott B, Gührs KH, Than ME. 2010. Structure and biochemical analysis of the heparin-induced E1 dimer of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 107:5381-86
65. Xue Y, Lee S, Ha Y. 2011. Crystal structure of amyloid precursor-like protein 1 and heparin complex suggests a dual role of heparin in E2 dimerization. Proc. Natl. Acad. Sci. USA 108:16229-34
66. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, et al. 2003. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. USA 100:1885-90
67. Salanga CL, Handel TM. 2011. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell Res. 317:590-601
68. Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, et al. 1997. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36:13570-78
69. Lortat-Jacob H, Grosdidier A, Imberty A. 2002. Structural diversity of heparan sulfate binding domains in chemokines. Proc. Natl. Acad. Sci. USA 99:1229-34
70. Kuschert GS, Hoogewerf AJ, Proudfoot AE, Chung CW, Cooke RM, et al. 1998. Identification of a glycosaminoglycan binding surface on human interleukin-8. Biochemistry 37:11193-201
71. Zhang X, Chen L, Bancroft DP, Lai CK, Maione TE. 1994. Crystal structure of recombinant human platelet factor 4. Biochemistry 33:8361-66
72. Ziarek JJ, Veldkamp CT, Zhang F, Murray NJ, Kartz GA, et al. 2013. Heparin oligosaccharides inhibit chemokine (CXC motif ) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif ) receptor 4 (CXCR4) N terminus. J. Biol. Chem. 288:737-46
73. Lau EK, Paavola CD, Johnson Z, Gaudry JP, Geretti E, et al. 2004. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J. Biol. Chem. 279:22294-305
74. Goodger SJ, Robinson CJ, Murphy KJ, Gasiunas N, Harmer NJ, et al. 2008. Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J. Biol. Chem. 283:13001-8
75. Tan K, Duquette M, Liu JH, Shanmugasundaram K, Joachimiak A, et al. 2008. Heparin-induced cisand trans-dimerization modes of the thrombospondin-1N- Terminal domain. J. Biol. Chem. 283:3932-41
76. Lietha D, Chirgadze DY, Mulloy B, Blundell TL, Gherardi E. 2001. Crystal structures ofNK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J. 20:5543-55
77. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. 2007. Structural basis for ligand and heparin binding to neuropilin B domains. Proc. Natl. Acad. Sci. USA 104:6152-57
78. Coles CH, Shen Y, Tenney AP, Siebold C, Sutton GC, et al. 2011. Proteoglycan-specific molecular switch for RPTPclustering and neuronal extension. Science 332:484-88
79. Shaw AS, Filbert EL. 2009. Scaffold proteins and immune-cell signalling. Nat. Rev. Immunol. 9:47-56
80. Jackson CM, Nemerson Y. 1980. Blood coagulation. Annu. Rev. Biochem. 49:765-811
81. Rau JC, Beaulieu LM, Huntington JA, Church FC. 2007. Serpins in thrombosis, hemostasis and fibrinolysis. J. Thromb. Haemost. 5(Suppl. 1):102-15
82. Björk I, Lindahl U. 1982. Mechanism of the anticoagulant action of heparin. Mol. Cell Biochem. 48:161-82
83. Olson ST, Björk I. 1991. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-Thrombin reaction. Elucidation from salt concentration effects. J. Biol. Chem. 266:6353-64
84. Li W, Johnson DJ, Esmon CT, Huntington JA. 2004. Structure of the antithrombin-Thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat. Struct. Mol. Biol. 11:857-62
85. Bray B, Lane DA, Freyssinet JM, Pejler G, Lindahl U. 1989. Anti-Thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem. J. 262:225-32
86. Johnson DJ, Li W, Adams TE, Huntington JA. 2006. Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J. 25:2029-37
87. Carter WJ, Cama E, Huntington JA. 2005. Crystal structure of thrombin bound to heparin. J. Biol. Chem. 280:2745-49
88. Dementiev A, Petitou M, Herbert JM, Gettins PG. 2004. The ternary complex of antithrombin- anhydrothrombin-heparin reveals the basis of inhibitor specificity. Nat. Struct. Mol. Biol. 11:863-67
89. Neese LL, Wolfe CA, Church FC. 1998. Contribution of basic residues of theDandHhelices in heparin binding to protein C inhibitor. Arch. Biochem. Biophys. 355:101-8
90. LiW,AdamsTE, Nangalia J, EsmonCT, Huntington JA. 2008. Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-Astructure of the heparin-bridged complex. Proc. Natl. Acad. Sci. USA 105:4661-66
91. Yang L, Manithody C, Rezaie AR. 2002. Contribution of basic residues of the 70-80-loop to heparin binding and anticoagulant function of activated protein C. Biochemistry 41:6149-57
92. Li W, Huntington JA. 2008. The heparin binding site of protein C inhibitor is protease-dependent. J. Biol. Chem. 283:36039-45
93. Ibrahimi OA, Zhang F, Hrstka SC, Mohammadi M, Linhardt RJ. 2004. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry 43:4724-30
94. Kalinina J,Dutta K, IlghariD, Beenken A,Goetz R, et al. 2012. The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure 20:77-88
95. Powell AK, Fernig DG, Turnbull JE. 2002. Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate: implications for dynamic assembly of a ternary signaling complex. J. Biol. Chem. 277:28554-63
96. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, et al. 2000. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6:743-50
97. Robinson CJ, Harmer NJ, Goodger SJ, Blundell TL, Gallagher JT. 2005. Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1FGFR2cheparin ternary complexes. J. Biol. Chem. 280:42274-82
98. Olsen SK, Li JY, Bromleigh C, Eliseenkova AV, Ibrahimi OA, et al. 2006. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev. 20:185-98
99. Fukuhara N, Howitt JA, Hussain SA, Hohenester E. 2008. Structural and functional analysis of slit and heparin binding to immunoglobulin-like domains 1 and 2 of Drosophila Robo. J. Biol. Chem. 283:16226-34
100. del Sol A, Tsai CJ, Ma B, Nussinov R. 2009. The origin of allosteric functional modulation: multiple pre-existing pathways. Structure 17:1042-50
101. Tsai CJ, del Sol A,Nussinov R. 2008. Allostery: Absence of a change in shape does not imply that allostery is not at play. J. Mol. Biol. 378:1-11
102. Langdown J, Belzar KJ, SavoryWJ, Baglin TP, Huntington JA. 2009. The critical role of hinge-region expulsion in the induced-fit heparin binding mechanism of antithrombin. J. Mol. Biol. 386:1278-89
103. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. 1997. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. USA 94:14683-88
104. Johnson DJ, Langdown J, Huntington JA. 2010. Molecular basis of factor IXa recognition by heparinactivated antithrombin revealed by a 1.7-Astructure of the ternary complex. Proc. Natl. Acad. Sci. USA 107:645-50
105. Al-Mohanna F, Parhar R, Kotwal GJ. 2001. Vaccinia virus complement control protein is capable of protecting xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells. Transplantation 71:796-801
106. Khan S, Nan R, Gor J, Mulloy B, Perkins SJ. 2012. Bivalent and co-operative binding of complement factor H to heparan sulfate and heparin. Biochem. J. 444:417-28
107. Ganesh VK, Smith SA, Kotwal GJ, Murthy KH. 2004. Structure of Vaccinia complement protein in complex with heparin and potential implications for complement regulation. Proc. Natl. Acad. Sci. USA 101:8924-29
108. Murthy KHM, Smith SA, Ganesh VK, Judge KW,Mullin N, et al. 2001. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell 104:301-11
109. Meri S, Pangburn MK. 1990. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc. Natl. Acad. Sci. USA 87:3982-86
110. Kreuger J, Spillmann D, Li JP, Lindahl U. 2006. Interactions between heparan sulfate and proteins: the concept of specificity. J. Cell Biol. 174:323-27
111. Lindahl U, Li JP. 2009. Interactions between heparan sulfate and proteins-design and functional implications. Int. Rev. Cell Mol. Biol. 276:105-59
112. Richard B, Swanson R, Olson ST. 2009. The signature 3-O-sulfo group of the anticoagulant heparin sequence is critical for heparin binding to antithrombin but is not required for allosteric activation. J. Biol. Chem. 284:27054-64
113. Turnbull JE, Fernig DG, Ke Y, WilkinsonMC, Gallagher JT. 1992. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J. Biol. Chem. 267:10337-41
114. Lortat-Jacob H, Turnbull JE, Grimaud JA. 1995. Molecular organization of the interferon γ-binding domain in heparan sulphate. Biochem. J. 310:497-505
115. Spillmann D,Witt D, Lindahl U. 1998. Defining the interleukin-8-binding domain of heparan sulfate. J. Biol. Chem. 273:15487-93
116. Kamimura K, Koyama T, Habuchi H, Ueda R, Masu M, et al. 2006. Specific and flexible roles of heparan sulfate modifications in Drosophila FGF signaling. J. Cell Biol. 174:773-78
117. Liu J, Shworak NW, Sinay P, Schwartz JJ, Zhang L, et al. 1999. Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J. Biol. Chem. 274:5185-92
118. Neugebauer JM, Cadwallader AB, Amack JD, Bisgrove BW, YostHJ. 2013. Differential roles for 3-OSTs in the regulation of cilia length and motility. Development 140:3892-902
119. Jemth P, Kreuger J, Kusche-Gullberg M, Sturiale L, Gimnez-Gallego G, Lindahl U. 2002. Biosynthetic oligosaccharide libraries for identification of protein-binding heparan sulfate motifs-exploring the structural diversity by screening for fibroblast growth factor (FGF) 1 and FGF2 binding. J. Biol. Chem. 277:30567-73
120. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. 1996. Heparin structure and interactions with basic fibroblast growth factor. Science 271:1116-20
121. Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT. 1998. J. Biol. Chem. 273:22936-42
122. Jastrebova N, Vanwildemeersch M, Lindahl U, Spillmann D. 2010. J. Biol. Chem. 285:26842-51
123. Luo Y, Ye S, Kan M, McKeehan WL. 2006. J. Cell. Biochem. 97:1241-58
124. Dulaney SB, Huang X. 2012. Strategies in synthesis of heparin/heparan sulfate oligosaccharides: 2000- present. Adv. Carbohydr. Chem. Biochem. 67:95-136
125. Turnbull JE, Gallagher JT. 1991. Sequence analysis of heparan sulphate indicates defined location of N-sulphated glucosamine and iduronate 2-sulphate residues proximal to the protein-linkage region. Biochem. J. 277:297-303
126. Stringer SE, Gallagher JT. 1997. Specific binding of the chemokine platelet factor 4 to heparan sulfate. J. Biol. Chem. 272:20508-14
127. Stringer SE, Forster MJ, Mulloy B, Bishop CR, Graham GJ, Gallagher JT. 2002. Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1alpha;. Blood 100:1543-50
128. Axelsson J, XuD,Na Kang B,Nussbacher JK,Handel TM, et al. 2012. Inactivation of heparan sulfate 2- O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood 120:1742-51
129. Carter NM, Ali S, Kirby JA. 2003. Endothelial inflammation: the role of differential expression of N-deacetylase/N-sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. J. Cell Sci. 116:3591-600
130. Krenn EC, Wille I, Gesslbauer B, Poteser M, van Kuppevelt TH, Kungl AJ. 2008. Glycanogenomics: A qPCR-Approach to investigate biological glycan function. Biochem. Biophys. Res. Commun. 375:297-302
131. Catlow KR,Deakin JA, Wei Z,Delehedde M, Fernig DG, et al. 2008. Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulfate density. J. Biol. Chem. 283:5235-48
132. Krilleke D, Ng YS, Shima DT. 2009. The heparin-binding domain confers diverse functions ofVEGF-A in development and disease: A structure-function study. Biochem. Soc. Trans. 37:1201-6
133. Shao C, Zhang F, Kemp MM, Linhardt RJ, Waisman DM, et al. 2006. Crystallographic analysis of calcium-dependent heparin binding to annexin A2. J. Biol. Chem. 281:31689-95
134. Capila I, VanderNoot VA,Mealy TR, Seaton BA, Linhardt RJ. 1999. Interaction of heparin with annexin V. FEBS Lett. 446:327-30
135. Norgard-Sumnicht KE, Varki NM, Varki A. 1993. Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. Science 261:480-83
136. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. 1998. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J. Clin. Investig. 101:877-89
137. Ricard-Blum S, Beraud M, Raynal N, Farndale RW, Ruggiero F. 2006. Structural requirements for heparin/heparan sulfate binding to type V collagen. J. Biol. Chem. 281:25195-204
138. Chakravarty L, Rogers L, Quach T, Breckenridge S, Kolattukudy PE. 1998. Lysine 58 and histidine 66 at the C-Terminal alpha;-helix of monocyte chemoattractant protein 1 are essential for glycosaminoglycan binding. J. Biol. Chem. 273:29641-47
139. Sheng GJ, Oh YI, Chang SK, Hsieh-Wilson LC. 2013. Tunable heparan sulfatemimetics formodulating chemokine activity. J. Am. Chem. Soc. 135:10898-901
140. Hanoulle X, Melchior A, Sibille N, Parent B, Denys A, et al. 2007. Structural and functional characterization of the interaction between cyclophilin B and a heparin-derived oligosaccharide. J. Biol. Chem. 282:34148-58
141. Cardin AD, Weintraub HJ. 1989. Molecular modeling of protein- glycosaminoglycan interactions. Arteriosclerosis 9:21-32
142. SobelM, Soler DF,Kermode JC,HarrisRB. 1992. Localization and characterization of a heparin binding domain peptide of human vonWillebrand factor. J. Biol. Chem. 267:8857-62
143. Margalit H, Fischer N, Ben-Sasson SA. 1993. Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues. J. Biol. Chem. 268:19228-31
144. Munoz EM, Linhardt RJ. 2004. Heparin-binding domains in vascular biology. Arterioscler. Thromb. Vasc. Biol. 24:1549-57
145. Moon AF, Xu Y,Woody SM, Krahn JM, Linhardt RJ, et al. 2012. Dissecting the substrate recognition of 3-O-sulfotransferase for the biosynthesis of anticoagulant heparin. Proc.Natl. Acad. Sci. USA109:5265-70
146. Xu Y, Masuko S, Takieddin M, Xu H, Liu R, et al. 2011. Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science 334:498-501
147. Peterson SB, Liu J. 2013. Multi-faceted substrate specificity of heparanase. Matrix Biol. 32:223-27
148. Schuksz M, Fuster MM, Brown JR, Crawford BE, Ditto DP, et al. 2008. Surfen, a small molecule antagonist of heparan sulfate. Proc. Natl. Acad. Sci. USA 105:13075-80